Pharmacokinetic investigations of Craviten. I. Spectrofluorometric determination of the drug in biological material.
A spectrofluorometric method for the quantitative determination of Craviten in serum, tissues and urine is described. The fluoroscence spectrum of that compound in acetic acid solution at excitation and emission wavelengths 270/380 nm respectively, is determined. A linear relationship between fluorescence and concentration exists over the range 0.25-10 microgram/ml and concentration of the drug as small as 0.15 microgram/ml may be determined.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000032:analysis*; D005029:Ethylenediamines / Q000032:analysis* / Q000097:blood / Q000652:urine; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D008168:Lung / Q000032:analysis; D009206:Myocardium / Q000032:analysis; D051381:Rats; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013154:Spleen / Q000032:analysis
D000889:Anti-Arrhythmia Agents; D005029:Ethylenediamines; C030706:butobendin